SAINTE-FOY, QUEBEC -- (MARKET WIRE) -- February 01, 2007 -- Dr. Andre P. Boulet, Chairman of the Board of Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, is pleased to announce that Dr. Rafick G. Henein has agreed to join the Company’s Board of Directors. Dr. Henein will initially sit on the Board of Bioxel as an observer starting February 1, 2007. His nomination will be subject to shareholders’ ratification at the Company’s forthcoming annual general meeting.
